New Structure Activity Relationship Insight into the Role of the C-3 Extension on Rifamycin Antimycobacterial...

Area of Science:

• Medicinal Chemistry
• Microbiology

Background:

• Rifamycin analogues are crucial in treating tuberculosis (TB).
• The C-3 extension of rifamycin is vital for drug efficacy and physicochemical properties.
• Understanding structure-activity relationships (SAR) of rifamycin C-3 modifications is key for developing new antimycobacterial agents.

Purpose of the Study:

• To screen novel rifamycin analogues with modifications at the C-3 extension for antimycobacterial activity.
• To identify specific C-3 modifications that enhance potency against Mycobacterium tuberculosis (Mtb).
• To investigate the correlation between physicochemical properties (logP) and biological activity.

Main Methods:

• Synthesis and screening of a series of rifamycin analogues with diverse C-3 extensions.
• Antimycobacterial activity testing against a wild-type Mtb strain in multiple growth media.
• Analysis of structure-activity relationships, focusing on the impact of C-3 modifications and logP.

Main Results:

• Several rifamycin analogues demonstrated potent antimycobacterial activity against Mtb.
• Compounds featuring rigid tertiary alicyclic hydrazones at the C-3 extension exhibited superior activity compared to those with amino compounds.
• A positive correlation was observed between lipophilicity (logP) and antimycobacterial activity.

Conclusions:

• The C-3 extension of rifamycin is a critical site for developing potent antimycobacterial drugs.
• Rigid tertiary alicyclic hydrazone moieties represent a promising structural motif for enhancing rifamycin activity.
• Modulating physicochemical properties, such as logP, is essential for optimizing antimycobacterial drug discovery efforts.